CYC Stock Overview
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CYC from our risk checks.
Cyclopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.78 |
| 52 Week High | AU$3.15 |
| 52 Week Low | AU$1.72 |
| Beta | 0.78 |
| 1 Month Change | -1.11% |
| 3 Month Change | -5.57% |
| 1 Year Change | -11.44% |
| 3 Year Change | -29.92% |
| 5 Year Change | 44.13% |
| Change since IPO | -5.07% |
Recent News & Updates
Recent updates
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash
Oct 28
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?
Apr 18Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth
Mar 31Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Oct 17Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Jun 09Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher
Mar 06Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation
Mar 02We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth
Oct 22Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
Jun 29Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
Apr 27Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic
Mar 01Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment
Feb 07Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?
Jan 02We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate
Dec 06Shareholder Returns
| CYC | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -0.3% | -1.7% | -2.2% |
| 1Y | -11.4% | 14.6% | 4.5% |
Return vs Industry: CYC underperformed the Australian Medical Equipment industry which returned 14.6% over the past year.
Return vs Market: CYC underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| CYC volatility | |
|---|---|
| CYC Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CYC has not had significant price volatility in the past 3 months.
Volatility Over Time: CYC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 87 | James McBrayer | www.cyclopharm.com |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.
Cyclopharm Limited Fundamentals Summary
| CYC fundamental statistics | |
|---|---|
| Market cap | AU$167.66m |
| Earnings (TTM) | -AU$4.70m |
| Revenue (TTM) | AU$27.14m |
6.2x
P/S Ratio-35.7x
P/E RatioIs CYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYC income statement (TTM) | |
|---|---|
| Revenue | AU$27.14m |
| Cost of Revenue | AU$10.26m |
| Gross Profit | AU$16.88m |
| Other Expenses | AU$21.58m |
| Earnings | -AU$4.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 62.21% |
| Net Profit Margin | -17.32% |
| Debt/Equity Ratio | 0% |
How did CYC perform over the long term?
See historical performance and comparison